In This Article:
Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images
Key Takeaways
-
Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.
-
The average weight loss among those taking the new drug was 15.7% after 68 weeks, compared to 3.1% for those taking a placebo.
-
Shares sank to their lowest point in over a year after the release of the first Phase 3 trial results for CagriSema in December.
Novo Nordisk's (NVO) U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.
In the second phase 3 study for the combination drug, the average weight loss among the roughly 1,200 patients in the study who took CagriSema was 15.7% of their body weight after 68 weeks, compared to 3.1% for those taking a placebo.
The study from the maker of Ozempic and Wegovy follows the first Phase 3 trial results for CagriSema in December that saw patients lose 22.7% of their body weight. Shares sank 17% following that study, as Bloomberg had reported ahead of the results that Novo Nordisk was aiming for a 25% weight loss with the new drug.
Novo Nordisk still has two more Phase 3 trials scheduled for CagriSema, and said Monday it still expects to submit the drug for regulatory approval in the first quarter of 2026.
Shares of the Danish drugmaker fell more than 7% Monday morning. They have risen recently following other trial results and solid sales of its current weight loss drugs, and are down 39% over the last year.
Read the original article on Investopedia